[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 27 of about 27
1. Corgna E, Betti M, Gatta G, Roila F, De Mulder PH: Renal cancer. Crit Rev Oncol Hematol; 2007 Dec;64(3):247-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cancer.
  • In Europe, renal cancer (that is neoplasia of the kidney, renal pelvis or ureter (ICD-9 189 and ICD-10 C64-C66)) ranks as the seventh most common malignancy in men amongst whom there are 29,600 new cases each year (3.5% of all cancers).
  • A familial history of renal carcinoma is also likely to increase the risk.
  • Renal carcinoma may remain clinically occult for most of its course.
  • Approximately 30% of patients with renal carcinoma present with metastatic disease, 25% with locally advanced renal carcinoma and 45% with localized disease.
  • Metastases are typically found in the lung, soft tissue, bone, liver, cutaneous sites, and central nervous system.
  • The most important staging technique is a computed tomography (CT) scan of the whole abdomen.
  • Five-year survival for patients with metastatic renal carcinoma is comprised between 0 and 20%.
  • Radical nephrectomy is the standard intervention for renal cancer.
  • Intrinsic resistance to chemotherapy has long been a hallmark of renal carcinoma.
  • Limited options are available for the systemic therapy, and no chemotherapeutic regimen is accepted as a standard of care.
  • Biologic agents represent the major effective therapies for widespread metastatic renal cancer.
  • An antiangiogenic strategy, the neutralization of VEGF, can slow the growth rate of advanced cancer.
  • [MeSH-major] Kidney Neoplasms / diagnosis. Kidney Neoplasms / pathology. Kidney Neoplasms / therapy

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662611.001).
  • [ISSN] 1040-8428
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 134
  •  go-up   go-down


2. Kolla SB, Hemal AK: An unusual case of transitional cell carcinoma of renal pelvis presenting with brain metastases. Int Urol Nephrol; 2007;39(3):747-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of transitional cell carcinoma of renal pelvis presenting with brain metastases.
  • During an evaluation for primary, he was found to be having transitional cell carcinoma (TCC) of right renal pelvis, for which palliative radical nephroureterectomy was performed, following which he received four cycles of paclitaxel and carboplatin chemotherapy.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Paclitaxel / therapeutic use. Ureter / surgery


3. Garcia del Muro X, Marcuello E, Gumá J, Paz-Ares L, Climent MA, Carles J, Parra MS, Tisaire JL, Maroto P, Germá JR: Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer; 2002 Feb 1;86(3):326-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer.
  • A multicentre phase II trial was undertaken to evaluate the activity and toxicity of docetaxel plus cisplatin as first-line chemotherapy in patients with urothelial cancer.
  • Thirty-eight patients with locally advanced or metastatic transitional-cell carcinoma of the bladder, renal pelvis or ureter received the combination of docetaxel 75 mg m(-2) and cisplatin 75 mg m(-2) on day 1 and repeated every 21 days, to a maximum of six cycles.
  • The median delivered dose-intensity was 98% (range 79-102%) of the planned dose for both drugs.
  • The median time to progression was 6.9 months, and the median overall survival was 10.4 months.
  • There was one toxic death in a patient with grade 4 granulocytopenia who developed acute abdomen.
  • Docetaxel plus cisplatin is an effective and well-tolerated regimen for the treatment of advanced urothelial cancer, and warrants further investigation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Paclitaxel / analogs & derivatives. Taxoids. Urologic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Time Factors. Treatment Outcome. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / pathology. Urothelium

  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 The Cancer Research Campaign
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2546-52 [10561321.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3173-81 [10506615.001]
  • [Cites] Ann Oncol. 1999 Nov;10(11):1385-8 [10631471.001]
  • [Cites] Ann Oncol. 1999 Dec;10(12):1461-5 [10643537.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):840-6 [10673526.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1058-61 [10694557.001]
  • [Cites] Eur J Cancer. 2000 Jan;36(1):74-9 [10741298.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2537-44 [10893284.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Clin Oncol. 2000 Sep 15;18(18):3247-55 [10986057.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1612-6 [11104554.001]
  • [Cites] J Urol. 2001 Jan;165(1):67-71 [11125366.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2527-33 [11331332.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 7;88(15):1078-9 [8683639.001]
  • [Cites] Br J Cancer. 1996 Nov;74(10):1655-9 [8932351.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1071-9 [9060547.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1853-7 [9164195.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):255-60 [9440750.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1844-8 [9586899.001]
  • [Cites] Urology. 1998 Jul;52(1):56-60 [9671871.001]
  • [Cites] Br J Cancer. 1998 Aug;78(3):370-4 [9703285.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2722-7 [9704723.001]
  • [Cites] J Clin Oncol. 1998 Oct;16(10):3392-7 [9779718.001]
  • [Cites] Br J Cancer. 1998 Nov;78(10):1342-5 [9823976.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • (PMID = 11875692.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2375206
  •  go-up   go-down


Advertisement
4. Muranaka T, Kunishima Y, Shigyo M, Kato R, Masumori N, Ito N, Tsukamoto T, Takagi Y, Seki M, Toida I: [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report]. Hinyokika Kiyo; 2007 Aug;53(8):581-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical site infection by bacillus Calmette-Guerin (BCG) after radical cystectomy, occurring after intravesical bcg therapy: a case report].
  • A 51-year-old man received 2 courses of intravesical bacillus Calmette-Guerin (BCG) therapy for carcinoma in situ of the bladder.
  • Two years after the therapy, he underwent left radical nephroureterectomy, cystectomy, urethrectomy and construction of an ileal conduit because of left renal pelvic cancer and severe atrophic bladder.
  • The histopathological diagnosis was carcinoma in situ of the left pelvis and ureter, and epithelioid cell granuloma of left kidney, prostate and bladder.
  • After the operation, he developed extensive surgical site infection (SSI) by BCG, the diagnosis of which was delayed.
  • He recovered from the SSI soon after anti-tuberculosis chemotherapy was begun.
  • [MeSH-major] BCG Vaccine / adverse effects. Carcinoma, Transitional Cell / drug therapy. Cystectomy. Surgical Wound Infection / etiology. Urinary Bladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874552.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


5. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T: The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res; 2002 Jun;8(6):1863-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter.
  • PURPOSE: We reported previously that angiogenesis evaluated by intratumor microvessel density (MVD), expression of such angiogenic factors as vascular endothelial cell growth factor (VEGF) and basic fibroblast growth factor (bFGF), and the matrix metalloproteinase-9:E-cadherin ratio (M:E ratio) could identify patients with advanced transitional cell carcinoma (TCC) of the bladder for whom chemotherapy and cystectomy will be unsuccessful.
  • EXPERIMENTAL DESIGN: We evaluated MVD by immunohistochemistry and the expression of angiogenic and metastasis-related factors by in situ hybridization in 55 nephroureterectomy specimens from patients who received no neoadjuvant therapy.
  • The expression level of matrix metalloproteinase type 9 (MMP-9) and type 2 (MMP-2) and the M:E ratio correlated with MVD.
  • Multivariate analysis indicated that the M:E ratio and E-cadherin expression were independent prognostic factors for disease progression and intravesical recurrence, respectively.
  • CONCLUSION: We suggest that the M:E ratio and E-cadherin expression may be targets for novel therapeutic strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Transitional Cell / blood supply. Kidney Neoplasms / blood supply. Neoplasm Proteins / metabolism. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cadherins / genetics. Cadherins / metabolism. Disease Progression. Endothelial Growth Factors / genetics. Endothelial Growth Factors / metabolism. Female. Fibroblast Growth Factor 2 / genetics. Fibroblast Growth Factor 2 / metabolism. Humans. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. Interleukin-8 / metabolism. Kidney Pelvis / metabolism. Lymphokines / genetics. Lymphokines / metabolism. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / genetics. Matrix Metalloproteinase 9 / metabolism. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. RNA, Messenger / metabolism. Survival Rate. Ureter / metabolism. Urinary Bladder / metabolism. Vascular Endothelial Growth Factor A. Vascular Endothelial Growth Factors

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12060629.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cadherins; 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Interleukin-8; 0 / Lymphokines; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; 103107-01-3 / Fibroblast Growth Factor 2; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


6. Makino H, Kametaka H, Koyama T, Seike K: [A case of unresectable advanced gallbladder cancer successfully treated by a combined administration of gemcitabine + CDDP]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2714-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unresectable advanced gallbladder cancer successfully treated by a combined administration of gemcitabine + CDDP].
  • His history included resections of the left kidney and ureter due to a cancer of the left renal pelvis.
  • The diagnosis was gallbladder cancer with infiltration of the liver and mesoduodenal ligament and lymphatic metastasis.
  • But his condition was judged not to be amenable to surgery: the procedure was limited to an exploratory laparotomy.
  • Chemotherapy composed of gemcitabine 1,000 mg/m2 + CDDP 25 mg/m2 (administered for 2 weeks followed by one week of no treatment, repeated for 8 cycles) was initiated on the 16th day of illness.
  • In a phase III trial (the UK ABC-02 trial) conducted by the American Society of Clinical Oncology (ASCO) in 2009, in which gemcitabine + CDDP combination therapy was compared against gemcitabine monotherapy to treat patients with advanced or metastatic biliary tract cancers, the overall duration of survival was significantly prolonged and the mortality risk reduced.
  • After one cycle applied while the patient was in the hospital, no adverse effects of the chemotherapy were found and a subsequent treatment was given on an outpatient basis.
  • No adverse effects attributable to the chemotherapy were noted until 8 cycles were completed.
  • With a careful observation of the clinical course, the procedure for unresectable gallbladder cancer shown here may be applied on an outpatient basis.
  • It is an effective and safe therapeutic modality, which may become a standard therapeutic procedure.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Gallbladder Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224689.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


7. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology; 2006 Mar;67(3):518-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Anderson Cancer Center from 1990 to 2004 to identify patients with primary nonurothelial tumors of the upper urinary tract.
  • We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.
  • RESULTS: Sixteen patients (1.9% of our database of patients with upper urinary tract tumors) were identified; 12 had squamous cell carcinoma, 2 had adenocarcinoma, 1 had sarcomatoid carcinoma, and 1 had small cell carcinoma.
  • The tumors were located in the renal pelvis in 10 and the ureter in 6.
  • Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy.
  • Ten patients received adjuvant chemotherapy.
  • The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%.
  • The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.
  • CONCLUSIONS: Primary nonurothelial carcinomas of the renal pelvis and ureter are rare.
  • Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527570.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79449; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


8. Thalmann GN, Markwalder R, Walter B, Studer UE: Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery. J Urol; 2002 Oct;168(4 Pt 1):1381-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term experience with bacillus Calmette-Guerin therapy of upper urinary tract transitional cell carcinoma in patients not eligible for surgery.
  • PURPOSE: Carcinoma in situ and urothelial tumors of the upper urinary tract become problematic in cases of bilateral occurrence or solitary kidney.
  • Perfusions with bacillus Calmette-Guerin (BCG) have been reported beneficial, however, only long-term results will determine the validity of this treatment.
  • MATERIALS AND METHODS: We retrospectively evaluated the results of BCG therapy for upper urinary tract disease in 37 patients.
  • All 37 patients had undergone previous surgical treatment for urothelial cancer, had a positive cytology or biopsy for upper urinary tract cancer and were ineligible for radical nephroureterectomy with a bladder cuff.
  • After placement of a 10Fr nephrostomy tube with the patient under local anesthesia 6 weekly perfusions of BCG were administered after radiological documentation of unhindered flow from the renal pelvis to the bladder or urinary diversion.
  • A total of 25 renal units were treated with curative intent for carcinoma in situ and 16 renal units were treated for Ta or higher urothelial tumors in an adjuvant setting after endoscopic resection.
  • RESULTS: In 37 patients 41 renal units were treated with BCG perfusions and were followed for a median of 42 months (range 8 to 137).
  • In 1 patient BCG inflammation and in 2 others severe septicemia developed after the first perfusion.
  • BCG perfusion therapy did not alter renal function.
  • Of the 37 patients 14 (38%) died of urothelial cancer, 11 of other causes (29%) and 12 (33%) are alive.
  • CONCLUSIONS: BCG perfusion therapy of the upper urinary tract for papillary tumors or carcinoma in situ is a valid treatment option with acceptable side effects for patients not amenable to conventional radical surgical therapy.
  • BCG therapy of upper urinary tract urothelial tumors may prevent patients from requiring dialysis and provides cure in those with carcinoma in situ of the upper urinary tract.
  • In this negatively selected patient population BCG buys time for some but does not provide cure except for carcinoma in situ.
  • [MeSH-major] BCG Vaccine / therapeutic use. Carcinoma in Situ / drug therapy. Carcinoma, Transitional Cell / drug therapy. Kidney Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Nephrectomy. Nephrostomy, Percutaneous. Perfusion. Retrospective Studies. Survival Rate. Ureter / pathology. Ureter / surgery. Ureteral Neoplasms / drug therapy. Ureteral Neoplasms / mortality. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / mortality. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urinary Diversion

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12352398.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCG Vaccine
  •  go-up   go-down


9. Sakuma T, Ujike T, Yoshida T, Ohashi H, Kawano K: [Urothelial carcinoma of ureter with neuroendocrine differentiation: a case report]. Hinyokika Kiyo; 2008 Feb;54(2):123-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urothelial carcinoma of ureter with neuroendocrine differentiation: a case report].
  • Urine cytology showed small cell carcinoma (SmCC) cells mixed with urothelial carcinoma (UC) cells.
  • With laparoscopic nephrectomy/open ureterectomy, distal end (approximately 10 cm) of the right ureter was tumorous and obstructed.
  • The tumor of lower-end of ureter tumor was SmCC, showing neuroendocrine differentiation such as pseudo-rosette, positive Grimelius stain, and chromogranin A/NCAM/synaptophysin immunostaining.
  • Proximal to this tumor, non-invasive UC spread superficially over entire length of the ureter to the renal pelvis.
  • Abrupt transition from invasive SmCC to non-invasive UC was observed in the middle of the ureter.
  • Post-operative adjuvant chemotherapy was discouraged due to senile dementia of the patient.
  • The patient died nine months after the operation because of systemic progression of cancer.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Ureteral Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18323171.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Takagi S, Gohji K, Iwamoto Y, Masuda H, Segawa N, Kiura H, Ueda H, Katsuoka Y: [Ureter cancer of complete double renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Dec;48(12):761-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureter cancer of complete double renal pelvis and ureter: a case report].
  • Intravenous pyelography, computerized tomography and magnetic resonance imaging revealed ureteral tumors of the complete left double renal pelvis and the ureter.
  • A transurethral resection of the tumor was done, and the pathological features revealed transitional cell carcinoma (PTa, grade 2).
  • A left nephroureterectomy and a partial cystectomy were also carried out; macroscopic examinations showed a non-papillary tumor on the middle portion of the left ureter originating from the upper pole of the kidney.
  • Microscopic examinations revealed transitional cell carcinoma (PT3, grade 3, PL1, PV1).
  • Adjuvant chemotherapy (M-VAC) was administered but discontinued because of severe side effects.
  • Dispite recurrence with retro-peritoneal lymph node metastasis, the patient is alive and again undergoing M-VAC chemotherapy 22 months after the initial surgery.
  • However, the evaluation of the chemotherapy was "no change".
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis / abnormalities. Neoplasms, Multiple Primary. Ureter / abnormalities. Ureteral Neoplasms / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local. Urinary Bladder Neoplasms / pathology. Urinary Bladder Neoplasms / surgery. Urologic Surgical Procedures

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12613013.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 16
  •  go-up   go-down


11. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewcz P, Shariat SF: Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol; 2010 Jun;57(6):1072-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy.
  • BACKGROUND: There is a lack of consensus regarding the prognostic significance of ureteral versus renal pelvic upper tract urothelial carcinoma (UTUC).
  • MEASUREMENTS: Data accrued included age, gender, race, surgical approach (open vs laparoscopic), tumor pathology (stage, grade, lymph node status), tumor location, use of perioperative chemotherapy, prior endoscopic therapy, urothelial carcinoma recurrence, and mortality from urothelial carcinoma.
  • Tumor location was divided into two groups (renal pelvis and ureter) based on the location of the dominant tumor.
  • RESULTS AND LIMITATIONS: The 5-yr recurrence-free and cancer-specific survival estimates for this cohort were 75% and 78%, respectively.
  • On multivariate analysis, only pathologic tumor (pT) classification (p<0.001), grade (p<0.02), and lymph node status (p<0.001) were associated with disease recurrence and cancer-specific survival.
  • When adjusting for these variables, there was no difference in the probability of disease recurrence (hazard ratio [HR]: 1.22; p=0.133) or cancer death (HR: 1.23; p=0.25) between ureteral and renal pelvic tumors.
  • Adding tumor location to a base prognostic model for disease recurrence and cancer death that included pT stage, tumor grade, and lymph node status only improved the predictive accuracy of this model by 0.1%.
  • CONCLUSIONS: There is no difference in outcomes between patients with renal pelvic tumors and with ureteral tumors following nephroureterectomy.
  • These data support the current TNM staging system, whereby renal pelvic and ureteral carcinomas are classified as one integral group of tumors.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Ureter / pathology. Urethral Neoplasms / pathology. Urothelium / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19619934.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


12. Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G: The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol; 2010 Oct;58(4):574-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center.
  • BACKGROUND: The prognostic impact of primary tumor location on outcomes for patients with upper-tract urothelial carcinoma (UTUC) is still contentious.
  • OBJECTIVE: To test the association between tumor location and disease recurrence and cancer-specific survival (CSS) in patients treated with radical nephroureterectomy (RNU) for UTUC.
  • Patients who had previous radical cystectomy, preoperative chemotherapy, previous contralateral UTUC, or metastatic disease at presentation were excluded.
  • Tumor location was categorized as renal pelvis or ureter based on the location of the dominant tumor.
  • Tumor location was not an independent predictor for recurrence (hazard ratio: 1.19; p=0.3), and there was no difference in the probability of disease recurrence between ureteral and renal pelvic tumors (p=0.18).
  • On survival analysis, we also found no differences between ureteral and renal pelvic tumors on probability of CSS (p=0.2).
  • CONCLUSIONS: Our study did not show any differences in recurrence and CSS rates between patients with ureteral and renal pelvic tumors treated with RNU.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [Cites] J Clin Oncol. 2009 Feb 1;27(4):612-8 [19075275.001]
  • [Cites] Eur Urol. 2008 Apr;53(4):794-802 [18207313.001]
  • [Cites] J Urol. 2009 Nov;182(5):2177-81 [19758662.001]
  • [Cites] Eur Urol. 2005 Sep;48(3):438-44 [16115524.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Urology. 1998 Oct;52(4):594-601 [9763077.001]
  • [Cites] Urology. 1997 Sep;50(3):321-9 [9301692.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):2016-20 [3167813.001]
  • [Cites] Cancer. 2009 Mar 15;115(6):1224-33 [19156917.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Urol. 2009 Sep;182(3):894-9 [19616243.001]
  • [Cites] Eur Urol. 2010 Jun;57(6):1072-9 [19619934.001]
  • [Cites] J Urol. 2000 Nov;164(5):1523-5 [11025695.001]
  • [Cites] J Urol. 2004 Feb;171(2 Pt 1):621-5 [14713773.001]
  • [CommentIn] Eur Urol. 2011 Apr;59(4):e23 [21255908.001]
  • [CommentIn] Eur Urol. 2011 Jan;59(1):e2 [20980096.001]
  • [CommentIn] J Urol. 2011 Feb;185(2):463 [22088622.001]
  • (PMID = 20637540.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ NIHMS628548; NLM/ PMC4174409
  •  go-up   go-down


13. Miao M, Kong CZ, Li ZH, Liu XK, Sun ZX: [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma]. Zhonghua Wai Ke Za Zhi; 2009 May 15;47(10):728-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical study for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma].
  • OBJECTIVE: To investigate the clinical methods for reducing bladder cancer recurrence after surgical treatment for renal pelvic carcinoma.
  • METHODS: From October 1997 to December 2007, the data of 227 patients undergoing total nephroureterectomy for clinically localized transitional cell carcinoma of the renal pelvis with follow-up results were analyzed retrospectively, including 126 cases of male and 101 cases of female, and the age was 34 to 78 years old.
  • Technique A was dissection along the ipsilateral ureter to the bladder wall.
  • Prophylactic intravesical chemotherapy included 3 method.
  • Method 1 was intraoperative intravesical chemotherapy and then administrated once a week, 10 times in total.
  • Method 2 was intraoperative intravesical chemotherapy and then administrated once a week from the 4(th) week after operation, 10 times in total.
  • Method 3 was intravesical chemotherapy was given once a week from the 4(th) week after operation, 10 times in total.
  • The time of follow-up was 1 to 10 years with regular cystoscopy.
  • Chi-square test and Logistic regression were used to analyzed the recurrence rate of bladder cancer.
  • RESULTS: Recurrence rate of bladder cancer was 27.8% (63/227).
  • The recurrence rates of bladder cancer in patients using technique A and B were 18.0% (7/39) and 12.5% (3/24), respectively (P < 0.05).
  • The postoperative recurrence rates of bladder cancer in patients using 3 kinds of intravesical chemotherapy regimen were 17.9% (11/67), 20.8% (10/48) and 33.3% (17/51), respectively.
  • There was significant difference between the recurrence rates of patients using method 1 and method 3 intravesical chemotherapy (P < 0.05).
  • CONCLUSION: Complete removal of the bladder mucosa circumferentially around the ureteral orifice, administration of the intraoperative intravesical chemotherapy instillation and instillation once a week may be a useful approach to reduce the recurrence of bladder cancer after operation for renal pelvic carcinoma.
  • [MeSH-major] Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Kidney Pelvis. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Chemotherapy, Cancer, Regional Perfusion. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Postoperative Care. Retrospective Studies


14. Chen WJ, Kuo JY, Chen KK, Lin AT, Chang YH, Chang LS: Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital. J Chin Med Assoc; 2005 Nov;68(11):522-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary urothelial carcinoma of the ureter: 11-year experience in Taipei Veterans General Hospital.
  • BACKGROUND: Urothelial carcinoma of the upper urinary tract is relatively rare, occurring in 5% of all urothelial tumors.
  • Ureteral urothelial carcinoma is even less common than that of the renal pelvis, accounting for about 25% of all upper urinary tract tumors.
  • The aim of this study was to evaluate the clinical behavior, survival, recurrence and prognostic information of primary ureteral urothelial carcinoma from our 11 years of experience at the Taipei Veterans General Hospital.
  • METHODS: We retrospectively reviewed 111 patients with ureteral urothelial carcinoma who had been treated in our hospital between January 1993 and December 2003.
  • Nephroureterectomy with bladder cuff excision was performed in 78 patients, 12 patients received segmental resection of the ureter, 4 received ureteroscopic laser coagulation, and 17 underwent chemotherapy or radiotherapy or both.
  • Disease recurrence in the nephroureterectomy group occurred in 36 patients (46.2%), with 17 (21.8%) at the urinary bladder, 2 (2.6%) at the retroperitoneum, 1 (1.3%) at the contralateral ureter, 6 (7.7%) with distant metastases to the lung, bone, distant lymph nodes or liver, and 10 (12.8%) at multiple sites.
  • The 5-year cancer-specific survival rate was 100% for pTa/is, 95.2% for pT1, 69.4% for pT2, and 43.8% for pT3.
  • All 3 pT4 cases died of cancer in a median of 12 months.
  • Significant prognostic factors for cancer-specific survival by univariate analysis were pT (p = 0.00001), stage (p = 0.00001), type of treatment (p = 0.00001) and grade (p = 0.0001).
  • On multivariate analysis, only stage (p = 0.0001) and grade (p = 0.014) were significant for cancer-specific and overall survival.
  • Tumor stage and grade are the only significant prognostic factors for both cancer-specific and overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16323396.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


15. Yasuda K, Kawa G, Kinoshita H, Matsuda T: [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report]. Hinyokika Kiyo; 2009 Mar;55(3):141-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Port-site metastasis of an upper urinary tract urothelial carcinoma after laparoscopic nephroureterectomy: a case report].
  • We report here a case of ureteral cancer in which port-site metastasis was suspected after a nephroureterectomy.
  • A tumor was found in his left renal pelvis and ureter by a computed tomographic (CT) scan.
  • The patient was diagnosed with a left upper urinary tract cancer with a clinical stage of T2N0M0.
  • The pathological diagnosis was an urothelial carcinoma, grade 2 > 3, INFbeta, pT3, pV1, pN2.
  • He received two courses of MVAC chemotherapy (methotrexate 50 mg, vinblastine 5 mg, adriamycin 50mg, cisplatin 120 mg) postoperatively.
  • Since retroperitoneal lymph node metastasis was observed three months later on a CT scan, the MVAC chemotherapy was repeated for three courses.
  • Nine months later, a tumor was found in the hypodermic beside the port-site, and a needle biopsy confirmed a metastatic urothelial carcinoma.
  • He received two courses of GP chemotherapy (gemcitabine 4,250 mg, paclitaxel 225 mg).
  • [MeSH-major] Carcinoma, Transitional Cell / pathology. Carcinoma, Transitional Cell / surgery. Laparoscopy. Neoplasm Seeding. Nephrectomy. Ureter / surgery. Ureteral Neoplasms / pathology. Ureteral Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19378825.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 17
  •  go-up   go-down


16. Zhang Y, Gu ZY, Tian Z, Yang C, Cai XY: Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case. Int J Oral Maxillofac Surg; 2010 Jul;39(7):737-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral metastasis from primary transitional cell carcinoma of the renal pelvis: report of a case.
  • Transitional cell carcinoma of the renal pelvis is initially a slow growing tumor arising from the transitional epithelium of the mucous membrane of the renal pelvis.
  • Recurrences occur in two forms: superficial bladder cancer and distant metastases.
  • The authors report an unusual case of transitional cell carcinoma of the renal pelvis metastasized to the oral cavity and lung simultaneously in a 74-year-old man, which occurred 1 year after a left nephroureterectomy.
  • The patient underwent six courses of chemotherapy (gemcitabine, oxaliplatin, fluorouracil and nedaplatin), and received radiotherapy for the oral lesion.
  • [MeSH-major] Carcinoma, Transitional Cell / secondary. Kidney Neoplasms / pathology. Kidney Pelvis / pathology. Mouth Neoplasms / secondary
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / pathology. Nephrectomy. Radiotherapy, Adjuvant. Ureter / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20236801.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


17. Bae KS, Ahn KI, Jeon SH, Huh JS, Chang SG: Efficacy of combined gemcitabine/cisplatin chemotherapy for locally advanced or metastatic urothelial cancer. Cancer Res Treat; 2006 Apr;38(2):78-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combined gemcitabine/cisplatin chemotherapy for locally advanced or metastatic urothelial cancer.
  • PURPOSE: We wanted to determine and report on the outcome of combined gemcitabine/cisplatin chemotherapy for patients suffering with locally advanced or metastatic urothelial cancer.
  • Group 1 (the adjuvant chemotherapy group) had undergone radical surgery with removal of evident tumor from the following primary sites: bladder (n=8), renal pelvis (n=7) and ureter (n=3).
  • Group 2 (the salvage chemotherapy group) had undergone palliative surgery with a remnant tumor at the following primary sites; bladder (n=23) and renal pelvis (n=2).
  • All the patients were given gemcitabine/ciplatin and they evaluated for the therapeutic effect and toxicity.
  • Toxicities: Grade 3 toxicities developed in 14 cycles during the total 232 cycles.
  • CONCLUSIONS: The results of this study confirm that adjuvant and salvage chemotherapy with using gemcitabine and cisplatin is tolerable and safe.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 1989 Aug;142(2 Pt 1):289-92 [2746745.001]
  • [Cites] J Urol. 2000 Jul;164(1):53-6 [10840423.001]
  • [Cites] Int J Urol. 2004 Jul;11(7):456-60 [15242352.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):768-72 [14967432.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1863-9 [14584068.001]
  • [Cites] Urologe A. 2003 Aug;42(8):1074-86 [14513232.001]
  • [Cites] Urol Int. 2003;71(1):37-40 [12845258.001]
  • [Cites] Intern Med J. 2005 Jun;35(6):336-42 [15892762.001]
  • [Cites] Am J Clin Oncol. 2005 Apr;28(2):195-200 [15803016.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2564-9 [9215826.001]
  • [Cites] Lancet Oncol. 2002 Dec;3(12):738-47 [12473515.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1921-7 [10784633.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2876-81 [10561365.001]
  • [Cites] Crit Rev Oncol Hematol. 2003 Feb;45(2):191-7 [12604129.001]
  • [Cites] Cancer. 1989 Dec 15;64(12):2448-58 [2819654.001]
  • [Cites] Can J Urol. 2002 Oct;9(5):1625-33 [12431323.001]
  • [Cites] World J Urol. 2002 Aug;20(3):158-66 [12196899.001]
  • [Cites] Curr Opin Urol. 2001 Sep;11(5):517-22 [11493774.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3068-77 [11001674.001]
  • [Cites] J Urol. 1985 Mar;133(3):403-7 [4038749.001]
  • (PMID = 19771264.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2741662
  • [Keywords] NOTNLM ; Cisplatin / Gemcitabine / Urologic neoplasms
  •  go-up   go-down


18. Fujii H, Nakamura T, Mikami K, Okihara K, Mizutani Y, Kawauchi A, Miki T: [Squamous cell carcinoma of the renal pelvis with elevation of G-CSF in the serum: a case report]. Hinyokika Kiyo; 2008 Nov;54(11):733-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma of the renal pelvis with elevation of G-CSF in the serum: a case report].
  • A 67-year-old man was admitted with left renal pelvic tumor.
  • Moreover, the serum granulocyte-colony stimulating factor (G-CSF) and squamous cell carcinoma antigen (SCC) were elevated.
  • Abdominal enhanced computed tomography (CT) and left retrograde pyelography showed left renal pelvic cancer T4N0M0.
  • He received neoadjuvant chemotherapy (M-VAC: cisplatin + methotrexate + vinblastin + doxorubicin, TN: paclitaxel + nedaplatin).
  • After neoadjuvant chemotherapy, left nephroureterectomy was performed because of normalization of the serum SCC and G-CSF.
  • Histological examination revealed squamous cell carcinoma of the renal pelvis.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Squamous Cell / diagnosis. Granulocyte Colony-Stimulating Factor / blood. Kidney Neoplasms / diagnosis. Kidney Pelvis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Neoadjuvant Therapy. Nephrectomy. Treatment Outcome. Ureter / surgery. Vinblastine / administration & dosage


19. Shishido T, Itou T, Ono Y, Arai Y, Miki M: [Adenocarcinoma of the renal pelvis and transitional cell carcinoma of the ureter occurring 11 years after radical cystectomy for bladder cancer: a case report]. Hinyokika Kiyo; 2001 Mar;47(3):187-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adenocarcinoma of the renal pelvis and transitional cell carcinoma of the ureter occurring 11 years after radical cystectomy for bladder cancer: a case report].
  • We report a case of upper urinary tract carcinoma which recurred 11 years after total cystectomy.
  • Carcinoma in situ was diagnosed pathologically.
  • The pathological diagnosis was transitional cell carcinoma, grade 3, pTis.
  • The right kidney was not visualized on IVP and computed tomography revealed a right renal irregular mass.
  • On the suspicion of a renal pelvic tumor, right total nephroureterectomy was done.
  • The pathologic diagnosis was renal pelvic adenocarcinoma and ureteral transitional cell carcinoma.
  • The patient was treated postoperatively with 3 cycles of systemic chemotherapy and radiotherapy.
  • [MeSH-major] Adenocarcinoma / etiology. Carcinoma, Transitional Cell / etiology. Cystectomy. Kidney Neoplasms / etiology. Kidney Pelvis. Neoplasms, Second Primary / etiology. Postoperative Complications. Ureteral Neoplasms / etiology. Urinary Bladder Neoplasms / surgery
  • [MeSH-minor] Humans. Male. Middle Aged. Time Factors


20. Holmäng S, Thomsen J, Johansson SL: Micropapillary carcinoma of the renal pelvis and ureter. J Urol; 2006 Feb;175(2):463-6; discussion 466-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micropapillary carcinoma of the renal pelvis and ureter.
  • MATERIALS AND METHODS: A clinical and histopathological review was performed in 943 patients with a neoplasm in the renal pelvis or ureter, diagnosed between 1971 and 1998.
  • Carcinoma in situ was identified in 64% of cases and vascular invasion was present in 81%.
  • CONCLUSIONS: The prognosis is poor since most patients with MPC of the renal pelvis and ureter initially present with advanced disease.
  • Stage for stage the prognosis is not different from that in nonMPC urothelial cell carcinoma.
  • However, radiotherapy and systemic chemotherapy appear to be ineffective.
  • [MeSH-major] Carcinoma, Papillary. Kidney Neoplasms. Kidney Pelvis. Ureteral Neoplasms

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406972.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Rassweiler J, Tsivian A, Kumar AV, Lymberakis C, Schulze M, Seeman O, Frede T: Oncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol; 2003 Jun;169(6):2072-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 567 procedures were performed in case of histologically proven cancer, whereas 531 represented only staging operations.
  • There were recurrences after nephroureterectomy for transitional cell carcinoma of the ureter in 1 patient, after radical nephrectomy for renal cell carcinoma in 1, growing teratoma after retroperitoneal lymph node dissection in 2, local recurrence of prostate cancer in 3 and after removal of an adrenal metastasis of melanoma in 1.
  • Two port site metastases (0.18% overall, 0.35% of histologically proved cases) occurred, including metastasis of small cell lung carcinoma after adrenalectomy and a residual mass following 2 cycles of chemotherapy after retroperitoneal lymph node dissection.
  • [MeSH-minor] Adrenalectomy. Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Seeding. Nephrectomy. Pelvis. Postoperative Complications. Prostatectomy. Ureter / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12771722.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Inahara M, Kojima S, Takei K, Naito H, Kito H, Yamazaki K, Ishida Y, Furuya Y: [Two cases of spontaneous rupture of upper urinary tract caused by the primary ureteral or renal pelvic tumor: a case report]. Hinyokika Kiyo; 2009 Jan;55(1):31-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of spontaneous rupture of upper urinary tract caused by the primary ureteral or renal pelvic tumor: a case report].
  • We report two cases of spontaneous urinary rupture caused by primary ureteral or renal pelvic cancer.
  • Magnetic resonance imaging showed left middle ureteral tumor and rupture of upper ureter.
  • Histological findings revealed urothelial carcinoma, G2, pT1, lt-u0, ew0, ly0, v1.
  • At five months postoperatively, he died of lymph node metastases after two courses of adjuvant chemotherapy.
  • Computer tomography showed left renal pelvic tumor with extravasation of urine.
  • Examination of surgical specimen revealed a renal pelvic tumor and rupture hole at the renal pelvis.
  • Histological finding revealed urothelial carcinoma, G3, pT3, lt-u0, ly0, v1.
  • One course of adjuvant chemotherapy was performed.
  • [MeSH-major] Carcinoma, Transitional Cell / complications. Kidney Diseases / etiology. Kidney Neoplasms / complications. Kidney Pelvis. Ureteral Diseases / etiology. Ureteral Neoplasms / complications
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Fatal Outcome. Humans. Male. Middle Aged. Nephrectomy. Rupture, Spontaneous. Treatment Outcome. Ureter / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Ureteral Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19227210.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 13
  •  go-up   go-down


23. Raman JD, Scherr DS: Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol; 2007 Aug;4(8):432-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of patients with upper urinary tract transitional cell carcinoma.
  • Multiple therapeutic options are available for the management of patients with upper urinary tract transitional cell carcinoma (TCC).
  • Radical nephroureterectomy with an ipsilateral bladder cuff is the gold-standard therapy for upper-tract cancers.
  • However, less invasive alternatives have a role in the treatment of this disease.
  • Endoscopic management of upper-tract TCC is a reasonable strategy for patients with anatomic or functional solitary kidneys, bilateral upper-tract TCC, baseline renal insufficiency, and significant comorbid diseases.
  • Distal ureterectomy is an option for patients with high-grade, invasive, or bulky tumors of the distal ureter not amenable to endoscopic management.
  • In appropriately selected patients, outcomes following distal ureterectomy are similar to that of radical nephroureterectomy.
  • Bladder cancer is a common occurrence following the management of upper-tract TCC.
  • Extrapolating from data on bladder TCC, both regional lymphadenectomy and neoadjuvant chemotherapy regimens are likely to be beneficial for patients with upper-tract TCC, particularly in the setting of bulky disease.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Urologic Neoplasms / diagnosis. Urologic Neoplasms / surgery
  • [MeSH-minor] Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / drug therapy. Kidney Neoplasms / surgery. Kidney Pelvis / pathology. Kidney Pelvis / surgery. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / surgery

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17673914.001).
  • [ISSN] 1743-4289
  • [Journal-full-title] Nature clinical practice. Urology
  • [ISO-abbreviation] Nat Clin Pract Urol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 107
  •  go-up   go-down


24. Cho KS, Cho NH, Park SY, Cho SY, Choi YD, Chung BH, Yang SC, Hong SJ: Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma. J Korean Med Sci; 2008 Jun;23(3):434-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of peripelvic fat invasion in pT3 renal pelvic transitional cell carcinoma.
  • Renal pelvic transitional cell carcinoma (TCC), which invades beyond muscularis into peripelvic fat or the renal parenchyma, is diagnosed as stage pT3 despite its structural complexity.
  • We evaluated the prognostic impact of peripelvic fat invasion in pT3 renal pelvic TCC.
  • Between 1986 and 2004, the medical records on 128 patients who were surgically treated for renal pelvic TCC were retrospectively reviewed.
  • On univariate analysis, sex, age, concomitant bladder tumors, concomitant ureter tumors, lymphadenectomy, adjuvant chemotherapy, tumor grade, multiplicity, renal parenchymal invasion, and carcinoma in situ did not influence the disease-specific survival (p>0.05).
  • In conclusion, peripelvic fat invasion is a strong prognostic factor in pT3 renal pelvic TCC.
  • Thus, systemic adjuvant therapy should be considered in the presence of peripelvic fat invasion, even if the lymph nodes are not involved.
  • [MeSH-major] Adipose Tissue / pathology. Carcinoma, Transitional Cell / pathology. Kidney Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Invasiveness. Pelvis. Prognosis. Retrospective Studies. Survival Analysis


25. Narita S, Nakano M, Matsuzaki M, Watanabe J, Morikawa H, Murata H, Oda H, Komatsu H: [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma]. Hinyokika Kiyo; 2005 Mar;51(3):155-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
  • We retrospectively evaluated the effect of the surgical resection of the remaining tumor after modified M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) (m-M-VAC) treatment for locally advanced or metastatic urothelial carcinoma.
  • In m-M-VAC therapy, methotrexate and vinblastine on 15 and 22 days were omitted from the classical M-VAC to avoid the discontinuation and the dose reduction, and duration of 1 course was shortened to 21 days from 28 days of the classical M-VAC.
  • Seven patients with locally invasive or metastatic carcinoma of the renal pelvis, ureter, and bladder, 6 males and 1 female, with a median age 64.1 years, ranging from 49 to 77 years received m-M-VAC chemotherapy without severe side effects.
  • In all patients, the residual viable carcinoma was completely resected and they achieved complete remission.
  • The median survival time was 20 months (range, 7 to 61).
  • Although further studies and long-term follow up are required, these results suggest that patients who present with locally advanced or metastatic urothelial carcinoma may benefit from surgical resection after m-M-VAC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Carcinoma, Transitional Cell / surgery. Urologic Neoplasms / drug therapy. Urologic Neoplasms / surgery
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymph Node Excision. Male. Methotrexate / administration & dosage. Middle Aged. Treatment Outcome. Vinblastine / administration & dosage

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852667.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  • [Number-of-references] 15
  •  go-up   go-down


26. Kakoi N, Miyajima A, Motizuku T, Mizuguchi Y, Asano T, Hayakawa M: [Carcinosarcoma of the renal pelvis and ureter: a case report]. Hinyokika Kiyo; 2002 Jan;48(1):29-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinosarcoma of the renal pelvis and ureter: a case report].
  • We report a case of carcinosarcoma of the renal pelvis and ureter arising in an 89-year-old man who presented at our hospital with gross hematuria.
  • Abdominal computed tomography, excretory pyelography, and retrograde pyelography demonstrated that left hydronephrosis was caused by an ureteral tumor.
  • Left urine cytology indicated transitional cell carcinoma.
  • The patient underwent chemotherapy and radiation therapy.
  • The surgical specimen showed carcinosarcoma in the renal pelvis and ureter histologically.
  • He has been free of cancer for 1.5 years.
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Kidney Pelvis. Male. Nephrectomy. Ureter / surgery

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11868382.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 5
  •  go-up   go-down


27. Kirkali Z, Tuzel E: Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol; 2003 Aug;47(2):155-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transitional cell carcinoma of the ureter and renal pelvis.
  • Transitional cell carcinoma (TCC) of ureter and renal pelvis is relatively uncommon.
  • Approximately 20-50% of patients with upper urinary tract (UUT) TCC have bladder cancer at some point on their course, whereas the incidence of UUT TCC after primary bladder cancer is 0.7-4%.
  • Nephroureterectomy with bladder cuff excision has been the mainstay of treatment.
  • Local resection may be appropriate for distal ureteral lesions especially when the disease is low grade and stage.
  • Adjuvant topical therapies appear to be safe but confirmation of any benefits awaits the results of further large studies.
  • More recently, laparoscopic techniques have become a viable alternative to open surgery, but long term cancer control data are lacking.
  • Adjuvant radiotherapy is ineffective, and systemic chemotherapy results in a low complete response rate for patients with metastases.
  • [MeSH-major] Carcinoma, Transitional Cell. Kidney Neoplasms. Ureteral Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Humans. Kidney Pelvis / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / etiology. Urinary Bladder Neoplasms / therapy






Advertisement